eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize natureâ€™s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
01/10/26	$5.760	-1.20%	636
30/09/26	$5.830	-4.43%	2,034
29/09/26	$6.100	+1.67%	2,044
28/09/26	$6.000	-3.92%	8,281
25/09/26	$6.245	-1.42%	9,188

Delayed Quote Nasdaq

More quotes

Market Closed - Nasdaq 23:30:00 01/10/2026 +03			5-day change	1st Jan Change
5.760 ^USD	-1.20%		-9.72%	-47.16%

09-12	EXoZymes, Inc., Q2 2026 Earnings Call, Aug 20, 2026
08-13	EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	54.11M 48.15M 44.93M 41.03M 76.94M 5.21B 78.09M 542M 210M 2.66B 203M 199M 8.55B	P/E 2024	-18.5x	P/E 2025	-9.97x
Enterprise Value	52.31M 46.55M 43.44M 39.67M 74.38M 5.04B 75.5M 524M 203M 2.57B 196M 192M 8.27B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	33.94%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	EXOZ	Delayed
CBOE	EXOZ	Real-time

09-12	EXoZymes, Inc., Q2 2026 Earnings Call, Aug 20, 2026
08-13	EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-24	EXoZymes receives $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery	CI
06-08	EXoZymes Prices $5.3 Million Offering	MT
05-14	EXoZymes, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-10	Exozymes Inc - announces common stock offering - SEC filing	RE
03-31	EXoZymes, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	EXoZymes, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-05	EXoZymes Inc. Reports Detailed Downline Performance Results from Its Recently Completed 100-liter Pilot Production Run of NCT	CI
12-12	EXoZymes, Inc. Achieves 100 Scale-Up of N-Trans-Caffeoyltyramine Production Process Using Its Proprietary Exozyme-Based, Cell-Free Biomanufacturing Platform	CI
11-14	EXoZymes, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-11	Certain Options of eXoZymes, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2025.	CI
11-11	Certain Restricted Stock Units of eXoZymes, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2025.	CI

eXoZymes, Inc. Stock

Stocks

EXOZ

US4618741098

Biotechnology & Medical Research

Valuation: eXoZymes, Inc.

Chart: eXoZymes, Inc.

Latest news: eXoZymes, Inc.

Last Transcript: eXoZymes, Inc.

Press Releases: eXoZymes, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: eXoZymes, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

09-08	EXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT	AQ
08-20	EXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today	AQ
08-18	EXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets	AQ
08-11	EXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026	AQ
07-23	EXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing	AQ

1 day	-1.20%
1 week	-9.72%
Current month	-1.20%
1 month	-14.41%
3 months	-31.67%
6 months	-23.30%
Current year	-47.16%

1 week	5.76	6.66
1 month	5.76	7.25
Current year	4.35	13.4
1 year	4.35	18.4
3 years	4.35	23.99
5 years	4.35	23.99
10 years	4.35	23.99

Manager	Title	Age	Since
Michael Heltzen CEO	Chief Executive Officer	45	01/02/2024
Paul Opgenorth CTO	Chief Tech/Sci/R&D Officer	43	01/04/2019
Tyler Korman CTO	Chief Tech/Sci/R&D Officer	47	01/04/2019

Director	Title	Age	Since
James Bowie BRD	Director/Board Member	67	01/04/2019
Chris Marlett CHM	Chairman	62	21/02/2025
Anthony DiGiandomenico BRD	Director/Board Member	60	01/04/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/14/26 A	Fouad Nawaz	Other	Chief Financial Officer	45,000	0.4848%
8/26/26 A	Michael Heltzen	Buy	Chief Executive Officer	505	0.0054%
8/19/26 A	Damien A. Perriman	Exercice	Executive/Senior Manager	39,224	0.4226%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXOZYMES, INC.	-1.20%	-9.72%	-60.08%	-	54.11M
WUXI APPTEC CO., LTD.	+4.16%	-0.36%	+49.37%	+94.17%	74.46B
ARGENX SE	-0.61%	+0.69%	+36.36%	+82.72%	60.14B
LONZA GROUP AG	-2.54%	-0.21%	+6.34%	+31.72%	48.15B
IQVIA HOLDINGS INC.	-3.02%	-2.67%	+37.26%	+32.51%	44.25B
REVOLUTION MEDICINES, INC.	+0.31%	+7.94%	+340.88%	+643.82%	43.99B
BEONE MEDICINES AG	-1.96%	-1.71%	+5.30%	+99.46%	41.61B
CELLTRION, INC.	+3.32%	+3.49%	+11.18%	+51.23%	29.97B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.16%	+36.77%	+22.78%	29.31B
INSMED INCORPORATED	-4.86%	-8.24%	-24.60%	+330.06%	24.93B
Average	-0.16%	+0.91%	+43.88%	+154.28%	39.69B
Weighted average by Cap.	+0.17%	+1.83%	+60.05%	+145.78%

	2024	2025
Net sales	-	-
Net income	-5.86M -5.22M -4.87M -4.44M -8.33M -565M -8.46M -58.76M -22.79M -288M -22.01M -21.53M -926M	-9.16M -8.15M -7.6M -6.94M -13.02M -882M -13.22M -91.82M -35.62M -449M -34.38M -33.64M -1.45B
Net Debt	-8.33M -7.41M -6.92M -6.32M -11.85M -803M -12.03M -83.54M -32.4M -409M -31.28M -30.6M -1.32B	-1.8M -1.6M -1.49M -1.36M -2.55M -173M -2.59M -18.01M -6.98M -88.14M -6.74M -6.6M -284M